In the field of nuclear medicine, it is necessary to perfect non-invasive diagnostic methods, and PulmoBioTech is contributing greatly to this need. The company recently announced the completion of bio-distribution studies concerning its PulmoBind molecular imaging agent.

The process of imaging on a cellular level requires the use of specialized molecules which are chemically engineered to bind to specific cells in the body, and these are then bonded to radioactive tracers. PulmoBind is a bonding agent that has been found to surpass those traditionally used in the field on several points. Essentially, it is a totally harmless substance known as adreno medullin which, upon injection, travels to and bonds with the tissue in the lungs more effectively than commonly used albumin macro-aggregates (AMAs). PulmoBind is safer as well, and provides the ability to capture images that are not possible with the older method.

Perhaps the best reason